Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cardiac renewal

PD-1–PD-L1 immunomodulatory pathway regulates cardiac regeneration

Nature Cardiovascular Research volume 3, pages 410–411 (2024)Cite this article

Subjects

Adult hearts have inherently limited regenerative capabilities, such that injury results in lasting damage. The situation is different in neonatal mouse hearts, however, where a new study reveals a role for the immunomodulatory PD-1–PD-L1 pathway in regulating regeneration after injury.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Immune checkpoint modulators and cardiac regeneration.

References

  1. Han, C. et al. Cell Res. 25, 1137–1151 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Tzahor, E. & Dimmeler, S. Science 377, eabm4443 (2022).

    Article  CAS  PubMed  Google Scholar 

  3. Aurora, A. B. et al. J. Clin. Invest. 124, 1382–1392 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Lavine, K. J. et al. Proc. Natl Acad. Sci. USA 111, 16029–16034 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Tan, Y., Duan, X., Wang, B., Liu, X. & Zhan, Z. Npj Regen. Med. 8, 7 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Dolejsi, T. et al. Eur. Heart J. 43, 2698–2709 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Li, J. et al. Theranostics 10, 8018–8035 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Aguilar, S. C. et al. Nat. Cardiovasc. Res. https://doi.org/10.1038/s44161-024-00447-7 (2024).

    Article  Google Scholar 

  9. Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L. & Kitsis, R. N. J. Clin. Invest. 131, e145186 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Tuttle, J. et al. N. Engl. J. Med. 388, 1853–1862 (2023).

    Article  CAS  PubMed  Google Scholar 

  11. Frangogiannis, N. G. Circ. Res. 110, 159–173 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

J.M. is supported by National Institutes of Health grants R01HL141466, R01HL155990, R01HL156021, R01HL160688 and R01HL170038. G.N.H. is supported by National Institutes of Health grants R01 HL157280 and R01 HL138456, Tobacco-Related Disease Research Program award P0558275, and American Heart Association Established Investigator award 23EIA1039425. J.Q. is supported by UCSF Catalyst Award 2024 and AHA’s Second Century Early Faculty Independence Award 24SCEFIA1246915.

Author information

Authors and Affiliations

  1. Section of Cardio-Oncology & Immunology, Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA, USA

    Juan Qin & Javid Moslehi

  2. Cardiovascular Research Institute (CVRI), University of California, San Francisco (UCSF), San Francisco, CA, USA

    Juan Qin, Guo N. Huang & Javid Moslehi

  3. Department of Physiology, University of California, San Francisco (UCSF), San Francisco, CA, USA

    Guo N. Huang

Authors
  1. Juan Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guo N. Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Javid Moslehi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Javid Moslehi.

Ethics declarations

Competing interests

J.M. has provided consulting or advisory roles for Pfizer, Novartis, Bristol-Myers Squibb, Deciphera, Takeda, AstraZeneca, Regeneron, Myovant, Kurome Therapeutics, Kiniksa Pharmaceuticals, Daiichi Sankyo, BeiGene, IQVIA, AskBio, Bitterroot Bio, Repare Therapeutics and Cytokinetics. J.M. is a co-inventor of a patent related to the use of abatacept in the treatment of ICI-myocarditis. J.Q. and G.N.H. declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qin, J., Huang, G.N. & Moslehi, J. PD-1–PD-L1 immunomodulatory pathway regulates cardiac regeneration. Nat Cardiovasc Res 3, 410–411 (2024). https://doi.org/10.1038/s44161-024-00461-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s44161-024-00461-9

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing